Sept 2011: UK study on new CMV treatment gets funding

     
At the moment the main treatment available for congenital CMV  is Ganciclovir. However it is an invasive treatment for a newborn baby (it is administered via intraveinous drip), and in some cases it can cause adverse effects. Also, Ganciclovir treatment must be started before a baby is 4 weeks old, leaving a very small window  of opportunity to combat the possible effects of CMV, especially if it is not diagnosed immediately at birth. [singlepic id=59 w=250 float=left]A new study has just been awarded funding to test a less invasive oral antiviral called Valganciclovir. The study will  test 6 weeks of valgancyclovir treatment in infants aged 1-18 months old, significantly increasing the potential window for treating congenital CMV. Please email info@cmvaction.org.uk if you are interested in finding out more. &;

Tags: 

  • news
     

Our Stories

Ben
Ben
On the 19th of March 2015, our little angel Ben was born sleeping at 30+5 weeks weighing 3lb 12&1/2 oz. We had a really healthy pregnancy but after a day of reduced movements &... Read more
Charlie
CMV has left four-year-old daughter Charlie facing a future without her hearing. Charlie’s Mum Lindsey had never heard of CMV during either of her pregnancies, yet she contracted the... Read more

Latest Events

Registered charity no: 1171773